139 related articles for article (PubMed ID: 8666122)
21. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1996 Aug; 46(8):766-73. PubMed ID: 9125276
[TBL] [Abstract][Full Text] [Related]
22. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
[TBL] [Abstract][Full Text] [Related]
23. Clinical experience with a 7-day estrogen patch: principles and practice.
Notelovitz M
Gynecol Endocrinol; 1998 Aug; 12(4):248-58. PubMed ID: 9798134
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol.
Scott RT; Ross B; Anderson C; Archer DF
Obstet Gynecol; 1991 May; 77(5):758-64. PubMed ID: 2014092
[TBL] [Abstract][Full Text] [Related]
25. Bioavailability of estradiol from two transdermal patches.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1996 Mar; 46(3):307-10. PubMed ID: 8901155
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of irritation and sensitisation of two 50 microg/day oestrogen patches.
Toole J; Silagy S; Maric A; Fath B; Quebe-Fehling E; Ibarra de Palacios P; Laurin L; Giguere M
Maturitas; 2002 Dec; 43(4):257-63. PubMed ID: 12468134
[TBL] [Abstract][Full Text] [Related]
27. Dose proportionality study of four doses of an estradiol transdermal system, Estradot.
Hossain M; Quebe-Fehling E; Sergejew T; Schmidt G; Skerjanec A; Ibarra de Palacios P; Krinsky L
Maturitas; 2003 Nov; 46(3):173-85. PubMed ID: 14585520
[TBL] [Abstract][Full Text] [Related]
28. [Bioavailability of 17 beta-estradiol after transdermal administration--dependence on the patch system].
Schmolling J; Kusche J; van der Ven H; Schander K
Zentralbl Gynakol; 1998; 120(3):121-5. PubMed ID: 9556902
[TBL] [Abstract][Full Text] [Related]
29. Comparative bioavailability study of an once-a-week matrix versus a twice-a-week reservoir transdermal estradiol delivery systems in postmenopausal women.
Baracat E; Haidar M; Castelo A; Tufik S; de Lima GR; Vieira JG; Peloso U; Casoy J
Maturitas; 1996 Apr; 23(3):285-91. PubMed ID: 8794422
[TBL] [Abstract][Full Text] [Related]
30. A comparative multicenter study of two transdermal estradiol replacement therapies in the treatment of postmenopausal symptoms.
Van Leusden HA; Albertyn G; Verlaine C; Van Ruymbeke J
Int J Fertil Menopausal Stud; 1993; 38(4):210-8. PubMed ID: 8401679
[TBL] [Abstract][Full Text] [Related]
31. Comparison of pharmacokinetic profiles of a 17 beta-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state.
Paoletti AM; Pilia I; Nannipieri F; Bigini C; Melis GB
Maturitas; 2001 Dec; 40(3):203-9. PubMed ID: 11731181
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of Menorest in two positive-controlled studies.
Pornel B
Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S35-7. PubMed ID: 8732472
[TBL] [Abstract][Full Text] [Related]
33. Significant differences in estradiol bioavailability from two similarly labelled estradiol matrix transdermal systems.
Buch AB; Shen LZ; Kelly SC; Russell DA; Sahota RS; Bixler CA; Moehrke W; Powell JH
Climacteric; 1999 Dec; 2(4):248-53. PubMed ID: 11910658
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of estradiol and of estrone during application of three strengths of an estradiol transdermal patch with active matrix.
Setnikar I; Rovati LC; Thebault JJ; Guillaume M; Mignot A; Renoux A; Gualano V
Arzneimittelforschung; 1997 Jul; 47(7):859-65. PubMed ID: 9272245
[TBL] [Abstract][Full Text] [Related]
35. HRT and long-term compliance: the efficacy and safety of Menorest.
Studd J; Panay N; Zamblera D; Leather AT
Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S21-5. PubMed ID: 8666123
[TBL] [Abstract][Full Text] [Related]
36. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group.
Int J Fertil Menopausal Stud; 1993; 38(1):5-11. PubMed ID: 8485612
[TBL] [Abstract][Full Text] [Related]
37. Improved patient acceptability with a transdermal drug-in-adhesive oestradiol patch.
Lake Y; Pinnock S
Aust N Z J Obstet Gynaecol; 2000 Aug; 40(3):313-6. PubMed ID: 11065040
[TBL] [Abstract][Full Text] [Related]
38. OESCLIM: an advanced delivery system for HRT.
Munoz A
Maturitas; 1999 Nov; 33 Suppl 1():S39-47. PubMed ID: 10661614
[TBL] [Abstract][Full Text] [Related]
39. Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch.
Järvinen A; Bäckström A; Elfström C; Viitanen A
Maturitas; 2001 Apr; 38(2):189-96. PubMed ID: 11306208
[TBL] [Abstract][Full Text] [Related]
40. [Systen--transdermal estradiol for substitution following surgical menopause].
Rachev E; Karag'ozov I
Akush Ginekol (Sofiia); 1995; 34(3):74-6. PubMed ID: 8743861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
